Table 1.
CYP3A4 inducers, product label advice and evidence for drug–drug interaction
| CYP3A4 inducer | Effect on abiraterone exposure | FDA label | EMA label | Evidence |
|---|---|---|---|---|
| Rifampicin | 55% decrease in exposure (AUC) | Avoid or increase dose frequency to twice daily | Avoid unless there is no alternative | Bernard et al.10 |
| Rifabutin | Unknown | Avoid or increase dose frequency to twice daily | Avoid unless there is no alternative | Not available |
| Rifapentine | unknown | Avoid or increase dose frequency to twice daily | Avoid unless there is no alternative | Not available |
| Carbamazepine | 67% decrease in exposure (AUC) | Avoid or increase dose frequency to twice daily | Avoid unless there is no alternative | This case |
| Phenytoin | unknown | Avoid or increase dose frequency to twice daily | Avoid unless there is no alternative | Not available |
| St. Johns Wort | unknown | Not mentioned in the label | Avoid unless there is no alternative | Not available |
| Phenobarbital | unknown | Avoid or increase dose frequency to twice daily | Avoid unless there is no alternative | Not available |